Keyword: Geoffrey Porges

As Pfizer advances a phase 3 rival to Regeneron and Sanofi's Dupixent, one analyst says it'll struggle to steal share because of side effects.

While investors don't fancy megamergers, smaller deals in oncology could be the winning ticket, analysts have found.

SVB Leerink analysts question whether Vertex's future CEO has the chops to find new R&D targets that will live up to the cystic fibrosis franchise.

SVB Leerink analysts are explaining why they like AbbVie's planned $63 billion acquisition of Allergan, and it all boils down to diversification.

With the aducanumab flop, shareholders are questioning management’s strategy—and an uncertain pipeline isn’t helping, either.

Celgene’s Revlimid may have slipped in previously untreated follicular lymphoma. But in the second-line setting, the drug has a win.

Gilead's third-quarter results offered a glimmer of hope for continued growth—particularly in HIV—but Wall Street skeptics weren't convinced.

Celgene ended a losing streak Monday with a Revlimid trial win, and one analyst thinks more rosy pipeline events could follow soon.

Celgene’s stock has taken a beating thanks to a string of bad news. But the situation isn’t as dire as its share price suggests, one analyst insists.